Revolution Medicines (NASDAQ:RVMD) Reaches New 1-Year High After Analyst Upgrade

Key Points

• Revolution Medicines reached a new 52-week high after Wedbush raised its price target from $201 to $225 and maintained an Outperform rating. Shares traded as high as $224.24, although the broader analyst consensus remains a more cautious “Moderate Buy” with a $179.39 target.
• The company received FDA approval for RASONQUE, its oral RAS-targeted therapy for previously treated metastatic pancreatic cancer, and set a list price of approximately $39,800 per month. The approval creates a near-term commercial opportunity, but reimbursement and affordability concerns could affect adoption.
• Risks remain despite strong investor enthusiasm: Revolution Medicines recently missed quarterly EPS expectations, while insiders sold substantial shares totaling about $38.2 million over three months. The stock’s roughly $47 billion valuation also leaves limited room for disappointing launch execution or sales growth.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday after Wedbush raised their price target on the stock from $201.00 to $225.00. Wedbush currently has an outperform rating on the stock. Revolution Medicines traded as high as $224.24 and last traded at $221.3210, with a volume of 476250 shares traded. The stock had previously closed at $215.44.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research note on Friday, July 17th. TD Cowen raised shares of Revolution Medicines to a "strong-buy" rating in a report on Monday. HC Wainwright upped their price objective on Revolution Medicines from $195.00 to $280.00 and gave the stock a "buy" rating in a report on Thursday. Royal Bank Of Canada increased their price objective on Revolution Medicines from $182.00 to $203.00 and gave the company an "outperform" rating in a research report on Thursday, August 6th. Finally, Oppenheimer restated an "outperform" rating and set a $230.00 target price on shares of Revolution Medicines in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $179.39.

Insiders Place Their Bets

In related news, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the completion of the sale, the chief financial officer directly owned 123,269 shares of the company's stock, valued at $20,749,870.77. The trade was a 13.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Stephen Michael Kelsey sold 4,175 shares of the company's stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $651,801.00. Following the completion of the sale, the insider owned 291,876 shares of the company's stock, valued at $45,567,681.12. This represents a 1.41% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 212,497 shares of company stock valued at $38,206,486 over the last three months. 7.60% of the stock is owned by insiders.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approves RASONQUE: The FDA approved RASONQUE (daraxonrasib), Revolution Medicines’ oral RAS-targeted therapy, for adults with previously treated metastatic pancreatic ductal adenocarcinoma or patients unable to receive combination chemotherapy. The company describes it as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, creating a significant commercial opportunity in a disease with limited treatment options. FDA approval announcement
• Positive Sentiment: Commercial launch and pricing established: Revolution Medicines priced RASONQUE at approximately $39,800 per month, providing investors with an initial benchmark for potential sales and reimbursement economics. Rapid FDA approval also shortens the path from clinical development to revenue generation. RASONQUE pricing article
• Positive Sentiment: Analyst support increased: TD Cowen upgraded RVMD, adding to an already favorable analyst backdrop. Recent firms including Oppenheimer, Truist Financial, RBC and Needham have maintained Buy or Outperform ratings and raised price targets, reinforcing confidence in the drug’s launch and broader RAS-inhibitor pipeline. TD Cowen upgrade
• Neutral Sentiment: Stock already reflects substantial optimism: RVMD has risen sharply over the past year and is trading close to its $220.34 12-month high, with a market capitalization of about $46 billion. Investors may therefore demand strong launch execution and sales growth to justify the current valuation.
• Negative Sentiment: High price could weigh on adoption: The nearly $40,000 monthly list price has prompted concerns that payer negotiations, reimbursement hurdles or affordability issues could slow uptake, which may explain why investor enthusiasm has been more measured despite the approval. Drug pricing concerns
• Negative Sentiment: Insider selling: Director Mark Goldsmith sold 80,000 shares for approximately $16.7 million, reducing his holdings by about 23%. The sale does not change the company’s fundamentals but may create a modest sentiment overhang, particularly after the stock’s substantial advance. Insider sale report

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Contravisory Investment Management Inc. bought a new position in shares of Revolution Medicines during the 2nd quarter valued at about $32,000. Global Retirement Partners LLC increased its stake in Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock worth $32,000 after purchasing an additional 361 shares in the last quarter. Torren Management LLC acquired a new stake in Revolution Medicines during the 4th quarter worth approximately $33,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines in the second quarter valued at approximately $37,000. Finally, Arax Advisory Partners acquired a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $38,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Price Performance

The company's 50-day moving average price is $191.27 and its 200-day moving average price is $147.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The company has a market cap of $47.29 billion, a P/E ratio of -25.05 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the business earned ($1.31) EPS. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source